Purpose: This systematic review aimed to evaluate the effects of reinforcing kidney and activating blood (RKAB) therapy for patients with premature ovarian failure (POF) from randomized controlled trials (RCTs).
Methods: We searched 7 databases and screened 11 studies from 267 articles by excluded the studies which did not reach inclusion criteria. Studies selection and data extraction were performed by two reviewers independently. Finally, the Review Manager Software was utilized to pool data, and evaluated the overall level of the evidence using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria.
Results: RKAB therapy significantly improve the serum levels of follicle-stimulating hormone (FSH) (MD-5.50, 95% CI: (-8.14, -2.86), P<0.0001), luteinizing hormone (LH) (MD-3.33, 95% CI: (-5.09, -1.57), P=0.0002) and estradiol (E2) (MD 6.82, 95% CI: (1.16, 12.47), P=0.02) as well as clinical curative efficiency (OR 2.60, 95% CI: (1.73, 3.89), P<0.00001) when compared with hormone replacement therapy (HRT) group.
Conclusion: The current evidence on RKAB therapy for POF is insufficient to draw a firm conclusion due to scarcity of studies with a low risk of bias and likely publication bias. Future rigorously designed studies are needed to confirm the effectiveness of RKAB therapy in patients with POF.